For instance, pan-sPLA2 inhibitors (e.g., varespladib), which inhibit group I/II/V/X sPLA2s altogether, have been reported to exert a poor therapeutic effect on atherosclerosis, arthritis, and allergy, probably because they blunt both offensive and defensive sPLA2s. This evidence concerns the gene PLA2G2D and Allergy.